Medtronic is witnessing a significant upturn, with a steady trajectory of mid-single-digit growth and improved financial stability, garnering positive market reactions. This revitalization is largely attributed to the successful introduction of innovative products and systems, including PulseSelect, Affera, Hugo, and Symplicity, which collectively contribute to a robust growth forecast.
A strategic move expected to further enhance Medtronic's investment profile and drive margin improvements post-2026 is the planned separation of its Diabetes business. This spin-off is anticipated to simplify the company's operational structure and sharpen its strategic focus.
Considering these positive shifts in fundamental performance and an appealing valuation, the company maintains a 'Buy' rating, projecting an upside towards a base case of $90 per share. This outlook is supported by a clear path towards sustained profitability and market expansion through both innovation and strategic restructuring.
